SCHEMBL3364238

SCHEMBL3364238

CC(=O)C[C@@H](C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1776110 1.00
SCHEMBL153744 1.00
SCHEMBL16540414 0.91 ALDH1A1 (0.52)
Dimethyl Sulfoxide SCHEMBL28104755 0.87 ALDH1A1 (0.48)
Methyl Isobutyl Ketone SCHEMBL106048 0.78 ALDH1A1 (0.88)
SCHEMBL3512468 0.77 ALDH1A1 (0.50)
SCHEMBL5317803 0.77 ALDH1A1 (0.50)
Methyl Isobutyl Ketone SCHEMBL16684652 0.77 TDP1 (0.74)
SCHEMBL14430862 0.77 ALDH1A1 (0.50)
SCHEMBL5665861 0.77 ALDH1A1 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037317-B2 Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds BUCK INSTITUTE FOR RESEARCH ON AGING (US) 2024-07-16 US disclosed
US-20230374249-A1 TEREPHTHALIC ACID ESTERS FORMATION 9449710 CANADA INC. (CA) 2023-11-23 US disclosed
US-20230125080-A1 TEREPHTHALIC ACID ESTERS FORMATION 9449710 CANADA INC. (CA) 2023-04-27 US disclosed
US-9598393-B2 Structural variants of mycolactones for use in modulating inflammation, immunity and pain INSTITUT PASTEUR (FR) 2017-03-21 US disclosed
US-20170007664-A1 CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES CYPRALIS LIMITED (GB) 2017-01-12 US disclosed
US-9382295-B2 Cyclic depsipeptide compounds and their uses CYPRALIS LIMITED (GB) 2016-07-05 US disclosed
US-20150259386-A1 CYCLIC DEPSIPEPTIDE COMPOUNDS AND THEIR USES CYPRALIS LIMITED (GB) 2015-09-17 US disclosed
US-20140330032-A1 MICROBIAL PRODUCTION OF CHEMICAL PRODUCTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS OPX BIOTECHNOLOGIES, INC. 2014-11-06 US disclosed
US-20140329771-A1 STRUCTURAL VARIANTS OF MYCOLACTONES FOR USE IN MODULATING INFLAMMATION, IMMUNITY AND PAIN INSTITUT PASTEUR (FR) 2014-11-06 US disclosed
WO-2013154325-A1 NOVEL ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING THE SAME ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) 2013-10-17 WO disclosed
WO-2013063120-A2 NMDA RECEPTOR MODULATORS AND USES THEREOF NORTHWESTERN UNIVERSITY (US) 2013-05-02 WO disclosed
EP-1763577-B1 ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS CODEXIS INC (US) 2010-10-06 EP disclosed
US-20100196974-A1 Chemically Inducible Expression of Biosynthetic Pathways METABOLIX, INC. 2010-08-05 US disclosed
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same TANABE SEIYAKU CO., LTD. (JP) 2009-01-01 US disclosed
US-20090005355-A1 Piperidine Compound and Process for Preparing the Same TANABE SEIYAKU CO., LTD. (JP) 2009-01-01 US disclosed
US-20070244158-A1 Piperdine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-18 US disclosed
US-20070244158-A1 Piperdine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-18 US disclosed
US-20070202333-A1 effected in the presence of a molecular cluster compound where molecules of cluster compound act as seed or nucleation point upon which nanoparticle growth may be initiated; high-temperature nucleation step is not required NANOCO TECHNOLOGIES LIMITED (GB) 2007-08-30 US disclosed
US-20070072859-A1 Pharmaceutical compounds ELI LILLY AND COMPANY (US) 2007-03-29 US disclosed
US-20070010695-A1 Diphosphines, preparation and uses thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2007-01-11 US disclosed